guest ::
| Home > Publications database > Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation. > print |
| Home > Publications database > Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation. > print |
| 001 | 179371 | ||
| 005 | 20240229145541.0 | ||
| 024 | 7 | _ | |a 10.3389/fimmu.2022.811094 |2 doi |
| 024 | 7 | _ | |a pmid:35359995 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8964102 |2 pmc |
| 024 | 7 | _ | |a altmetric:124629520 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00622 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Hasche, Daniel |0 P:(DE-He78)93b84588571c05b85df1c0916f740e98 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Isoforms of the Papillomavirus Major Capsid Protein Differ in Their Ability to Block Viral Spread and Tumor Formation. |
| 260 | _ | _ | |a Lausanne |c 2022 |b Frontiers Media |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1649153221_16166 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F030#LA:F030# |
| 520 | _ | _ | |a Notably, the majority of papillomaviruses associated with a high cancer risk have the potential to translate different isoforms of the L1 major capsid protein. In an infection model, the cutaneous Mastomys natalensis papillomavirus (MnPV) circumvents the humoral immune response of its natural host by first expressing a 30 amino acid extended L1 isoform (L1LONG). Although inducing a robust seroconversion, the raised antibodies are not neutralizing in vitro. In contrast, neutralizing antibodies induced by the capsid-forming isoform (L1SHORT) appear delayed by several months. We now provide evidence that, although L1LONG vaccination showed a strong seroconversion, these antibodies were not protective. As a consequence, virus-free animals subsequently infected with MnPV still accumulated high numbers of transcriptionally active viral genomes, ultimately leading to skin tumor formation. In contrast, vaccination with L1SHORT was completely protective. This shows that papillomavirus L1LONG expression is a unique strategy to escape from antiviral immune surveillance. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Mastomys coucha |2 Other |
| 650 | _ | 7 | |a NMSC (non-melanoma skin cancer) |2 Other |
| 650 | _ | 7 | |a cutaneous papillomaviruses |2 Other |
| 650 | _ | 7 | |a immune escape mechanism |2 Other |
| 650 | _ | 7 | |a major capsid protein (L1) |2 Other |
| 650 | _ | 7 | |a neutralizing antibodies |2 Other |
| 650 | _ | 7 | |a vaccination |2 Other |
| 650 | _ | 7 | |a viral infection |2 Other |
| 700 | 1 | _ | |a Ahmels, Melinda |0 P:(DE-He78)bc487db59becdf534f61e0fb31bc801d |b 1 |u dkfz |
| 700 | 1 | _ | |a Braspenning-Wesch, Ilona |0 P:(DE-He78)810ef819c7d86928b119192db5730fc7 |b 2 |u dkfz |
| 700 | 1 | _ | |a Stephan, Sonja |0 P:(DE-He78)fd869847d6731bf306dce72ed1ef343b |b 3 |u dkfz |
| 700 | 1 | _ | |a Cao, Rui |0 P:(DE-He78)aa2868b980249801b3207f4fbf65660b |b 4 |
| 700 | 1 | _ | |a Schmidt, Gabriele |0 P:(DE-He78)e8868a5fc184fe2e756d7e11ad1ac748 |b 5 |u dkfz |
| 700 | 1 | _ | |a Müller, Martin |0 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579 |b 6 |u dkfz |
| 700 | 1 | _ | |a Rösl, Frank |0 P:(DE-He78)97f27961503f8b3233697cbad1bbed4e |b 7 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.3389/fimmu.2022.811094 |g Vol. 13, p. 811094 |0 PERI:(DE-600)2606827-8 |p 811094 |t Frontiers in immunology |v 13 |y 2022 |x 1664-3224 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:179371 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)93b84588571c05b85df1c0916f740e98 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)bc487db59becdf534f61e0fb31bc801d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)810ef819c7d86928b119192db5730fc7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)fd869847d6731bf306dce72ed1ef343b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)aa2868b980249801b3207f4fbf65660b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)e8868a5fc184fe2e756d7e11ad1ac748 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)97f27961503f8b3233697cbad1bbed4e |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-01-29 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-01-29 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b FRONT IMMUNOL : 2021 |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-23 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b FRONT IMMUNOL : 2021 |d 2022-11-23 |
| 920 | 2 | _ | |0 I:(DE-He78)F030-20160331 |k F030 |l F030 Virale Transformationsmechanismen |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F030-20160331 |k F030 |l F030 Virale Transformationsmechanismen |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)W210-20160331 |k W210 |l Lichtmikroskopie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)F035-20160331 |k F035 |l F035 Tumorvirus-spez. Vakzinierungsstrategie |x 2 |
| 920 | 0 | _ | |0 I:(DE-He78)F030-20160331 |k F030 |l F030 Virale Transformationsmechanismen |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F030-20160331 |
| 980 | _ | _ | |a I:(DE-He78)W210-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F035-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|